Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling

Abstract The estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generate slow-growing resistant cells that fo...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kristine J. Fernandez, Ghazal Sultani, Max Nobis, Brian Gloss, Leila Eshraghi, Amy E. McCart Reed, Sarah Alexandrou, Christine Lee, Daniel L. Roden, Emily I. Jones, Maryam Hasha Simad, Ewan K. A. Millar, Nenad Bartonicek, Samantha R. Oakes, Fatima Valdes-Mora, Yolanda Colino-Sanguino, Ellie T. Y. Mok, Hannah L. Williams, Jamie R. Kutasovic, Margaret C. Cummings, Janett Stoehr, Victoria Lee, Kate Harvey, Sunny Wu, Sunil R. Lakhani, Peter T. Simpson, Thomas R. Cox, Lisa M. Ooms, Christina A. Mitchell, Rob Salomon, Alexander Swarbrick, David Gallego-Ortega, Elgene Lim, Paul Timpson, C. Elizabeth Caldon
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2026-05-01
Saila:	Nature Communications
Sarrera elektronikoa:	https://doi.org/10.1038/s41467-026-70683-x
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!